Philadelphia Investment Partners’s AbbVie ABBV Stock Holding History

Philadelphia Investment Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$539K	Hold	2,147	–	–	0.34%	53
2026 Q1	$467K	Buy	+2,147	New	+$476K	0.32%	52

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Philadelphia Investment Partners's ABBV Position: Q2 2026 in Review

Philadelphia Investment Partners held its AbbVie (ABBV) position steady in Q2 2026 at 2,147 shares worth $539K. The position accounts for 0.34% of the portfolio, ranked #53.

Philadelphia Investment Partners first reported a position in ABBV in Q1 2026 and has held it in 2 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Philadelphia Investment Partners held 2,147 shares of AbbVie worth $539K as of Q2 2026.
Philadelphia Investment Partners left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.34% of Philadelphia Investment Partners's portfolio in Q2 2026, its #53 holding.
Philadelphia Investment Partners first reported a position in AbbVie in Q1 2026 and has held it in 2 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Philadelphia Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.